MBLi program: Metallo ß-lactamase inhibitor.
Antabio is developing a novel, safe and potent inhibitor of bacterial MBLs
to be administered with a carbapenem for treating CRE infections in hospitalized patients. Antabio’s preclinical
candidate ANT2681 potentiates carbapenem efficacy against NDM-CRE strains in animal infection models and restores
carbapenem susceptibility in a broad range of MBL-producing clinical isolates (including all NDM variants that are
prevalent in China). Pre-clinically ANT2681 shows superior NDM inhibition compared to competitors, including VNRX5133 recently in-licensed by Everest Medicines for development in China. Initiation of Phase 1 studies for ANT2681 is
expected in 2020.
SBLi: Serine B-lactamase inhibitor
Antabio has discovered a novel and potent SBL inhibitor with broad coverage against
key SBL enzymes, including ESBLs, KPC and OXA-type carbapenemases in Enterobacteriaceae, Acinetobacter baumannii
and Pseudomonas aeruginosa. Antabio’s candidate ANT3310 restores meropenem efficacy against both OXA and KPC CREs and is the only combination with potent activity vs OXA-producing A. baumannii, thus addressing a major unmet
medical need in China, and also ranked n°1 global AMR priority by WHO. As such, ANT3310 is positioned to be the best
SBLi in the market with a unique CRE and carbapenem-resistant A. baumannii (CRAB) target product profile.
PEi: Pseudomonas Elastase Inhibitors
This program, aimed at developing novel small molecule drugs for the treatment
of chronic Pseudomonas infections in Cystic fibrosis (CF) patients, is currently funded by a CARB-X award (potentially
$8.9 Million) to continue development up to clinical trials. ANTABIO has developed a safe and tractable lead series with
potent whole cell activity against the Pseudomonas LasB elastase secreted by clinical CF isolates and excellent potential
for inhaled administration.